Breaking
Troy keeps season alive, ousts Ole Miss at MCWS Could Farage quit? Questions swirl over Reform UK leader’s future At least 25 people die in US as record heatwave scorches swaths of country National Guard members on patrol in Memphis fatally shoot man during pursuit, police say Delta pilot reports a close encounter with a July Fourth firework before landing in Chicago Benedict's Law to overhaul school allergy training Shelter-in-place order at Azteca over severe weather before Mexico-England Interior secretary says administration will use the same company to repair Reflecting Pool Mexico v England: World Cup 2026 last 16 tie hit by thunderstorm in buildup – live Uber’s European expansion plans may have hit a speed bump
NEWSREEL
The day, in 30-second reels.
--:--:--
Science / Reel
Science · Video brief

Researchers launch study on Ebola treatments as Congo outbreak worsens

In response to a worsening Ebola outbreak in Congo, researchers are testing Remdesivir and MBP134 to combat the Bundibugyo virus. With over 1,400 diagnosed and 438 fatalities, this urgent study by the WHO in Ituri province aims to improve s...

AP News· Jul 2, 2026 · 11:40 PM · 5 views

In response to a worsening Ebola outbreak in Congo, researchers are testing Remdesivir and MBP134 to combat the Bundibugyo virus. With over 1,400 diagnosed and 438 fatalities, this urgent study by the WHO in Ituri province aims to improve survival rates. Can these new treatments turn the tide? #Ebola #Congo #HealthCrisis #MedicalResearch #WHO

Originally reported by AP News. Read the full story →

More in Science

Science Scien
Science

The Guardian view on gene-edited humans: darker uses must be acknowledged alongside medical ones | Editorial

The Guardian· 3 hours ago
Science Scien
Science

Bomb the Arctic, dam the Mediterranean and build a second moon: five outlandish plans to remodel our climate

The Guardian· 5 hours ago
Science Scien
Science

Elon Musk posted twice as often on UK race and immigration as about SpaceX in IPO run-up

The Guardian· 1 day ago

0 Comments

No comments yet. Be the first.